stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Total debt
GeneDx Holdings Corp.'s total debt at the end of fiscal 2025 was $48.2M, down 7.20% from $51.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $96.8M. Over the past ten years it has ranged from $6.3M (fiscal 2022) to $52.7M (fiscal 2023); the current reading is higher than 67% of that period. GeneDx Holdings Corp. ranks 24th of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $48.2M | (7.20%) |
| FY2024 | $51.9M | (1.47%) |
| FY2023 | $52.7M | 743.01% |
| FY2022 | $6.3M | (43.18%) |
| FY2021 | $11.0M | (72.33%) |
| FY2020 | $39.7M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $96.8M | 0.11% |
| Mar 2026 | $96.7M | 100.79% |
| Dec 2025 | $48.2M | (6.60%) |
| Sep 2025 | $51.6M | (0.20%) |
| 17 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| OPK OPKO Health, Inc. compare | $462.7M |
| NEO NeoGenomics, Inc. compare | $378.8M |
| ADPT Adaptive Biotechnologies Corporation compare | $334.9M |
| WGS GeneDx Holdings Corp. | $96.8M |
| PSNL Personalis, Inc. compare | $39.2M |
| CDNA CareDx, Inc. compare | $35.2M |
| VCYT Veracyte, Inc. compare | $14.0M |
| CSTL Castle Biosciences, Inc. compare | $4.2M |
| FRNM Freenome, Inc compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement